The FDA updated the label for axicabtagene ciloleucel (Yescarta), removing the prior contraindication for treating patients with primary central nervous system (CNS) lymphoma. The agency approved the label change after Dana‑Farber research and submitted clinical evidence supporting use in this high‑risk population. The change expands an approved CAR‑T indication into a challenging CNS tumor setting and reduces a prior barrier for clinicians considering CD19‑directed cell therapy for CNS lymphoma patients who previously lacked approved CAR‑T options.